These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11728242)

  • 41. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456
    [No Abstract]   [Full Text] [Related]  

  • 43. Repurposing Cilostazol for Raynaud's Phenomenon.
    El-Hachem N; Fardoun MM; Slika H; Baydoun E; Eid AH
    Curr Med Chem; 2021; 28(12):2409-2417. PubMed ID: 32881655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Vasodilation caused by inhibition of calcium ions as a factor of increasing oxygen transport in peripheral vascular diseases].
    Pola P; Savi L; Dal Lago A; Zucchiatti V
    Clin Ter; 1977 Jun; 81(5):417-31. PubMed ID: 884936
    [No Abstract]   [Full Text] [Related]  

  • 45. [Medical treatment of the Raynaud phenomenon].
    Zicot M
    Phlebologie; 1987; 40(1):47-9. PubMed ID: 3033711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [DIAGNOSIS AND TREATMENT OF OBLITERATIVE PERIPHERAL VASCULAR DISEASES].
    BEGELMAN AA; BOGDANOVA EA; BUKHTEEVA NF
    Khirurgiia (Mosk); 1964 Apr; 40():140-5. PubMed ID: 14169190
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical trials with defibrotide in vascular disorders.
    Cimminiello C
    Semin Thromb Hemost; 1996; 22 Suppl 1():29-34. PubMed ID: 8807726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of a new sympatholytic drug in therapy of chronic peripheral obliterating artery diseases].
    Vittori C; Taborelli G; Taborelli R
    Minerva Cardioangiol; 1965 Sep; 13(9):585-91. PubMed ID: 5851172
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment of Raynaud's phenomenon].
    Levy Y; Shoenfeld Y
    Harefuah; 1993 Mar; 124(5):288-91. PubMed ID: 8098699
    [No Abstract]   [Full Text] [Related]  

  • 50. [Calcium antagonists in the treatment of Raynaud's syndrome and in the treatment of esophageal spasm].
    Kahan A; Amor B; Menkès CJ
    Rev Prat; 1988 Nov; 38(27):1986-8. PubMed ID: 3206151
    [No Abstract]   [Full Text] [Related]  

  • 51. [Therapeutic use of prostacyclin in cardiovascular pathology].
    Martelli M; Nicolosi G
    Minerva Med; 1983 Nov; 74(44):2665-70. PubMed ID: 6419178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Contribution to the therapy of juvenile and arteriosclerotic chronic peripheral obliterating artery diseases with a new sympatholytic drug].
    Stoppani L; Lo Cuoco A
    Minerva Cardioangiol; 1966 Mar; 14(3):163-5. PubMed ID: 5937431
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment for Raynaud's: beyond calcium channel blockers.
    Bergstrom KG; Perelman RO
    J Drugs Dermatol; 2008 May; 7(5):497-500. PubMed ID: 18505148
    [No Abstract]   [Full Text] [Related]  

  • 54. [The use of intrathecal phenol solutions in vascular diseases of the lower exremities].
    Papo I; Visca A
    Minerva Cardioangiol; 1967 Feb; 15(2):169-71. PubMed ID: 5632412
    [No Abstract]   [Full Text] [Related]  

  • 55. [IMPORTANCE OF THE NERVOUS MECHANISMS IN THE PATHOGENESIS OF PERIPHERAL OBLITERATING ARTERIOPATHY (CLINICAL CONTRIBUTION)].
    PRATESI F; BARTOLI V
    Rass Neurol Veg; 1963 Dec; 17():301-19. PubMed ID: 14122982
    [No Abstract]   [Full Text] [Related]  

  • 56. [Drugs for the treatment of arterial blood flow disorders].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1988 Jan; 132(2):51-3. PubMed ID: 3340217
    [No Abstract]   [Full Text] [Related]  

  • 57. [The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy].
    D'Ayala Valva G
    Recenti Prog Med; 1966 Jun; 40(6):XIX-XXXVI. PubMed ID: 6014405
    [No Abstract]   [Full Text] [Related]  

  • 58. [The use of mydocalm in the treatment of vascular diseases of the extremities].
    Liubishchev SA
    Klin Med (Mosk); 1967 Jan; 45(1):100-2. PubMed ID: 5613382
    [No Abstract]   [Full Text] [Related]  

  • 59. [Attempts of treatment of peripheral blood circulation disorders including thromboembolic and hyperlipemic conditions with pentosanpolysulfoester (PPE)].
    Szirmai E; Celander DR
    Pharmazie; 1968 Sep; 23(9):501-2. PubMed ID: 4180427
    [No Abstract]   [Full Text] [Related]  

  • 60. [PERIPHERAL VASODILATOR ACTION OF MYDETON].
    SOOS S
    Orv Hetil; 1964 Jul; 105():1369-72. PubMed ID: 14181919
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.